Management of oxidative stress and other pathologies in Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms, preclinical compounds, and in vitro studies
PubMed 31440798 · doi:10.1007/s00204-019-02538-y
What was done
This narrative review synthesized research on multitarget-directed drug strategies for Alzheimer's disease, focusing on combinations that address acetylcholinesterase activity, metal-induced oxidative stress, neuroinflammation, and amyloid-beta aggregation. Evaluated approaches included tacrine-derived hybrid molecules and natural substances such as flavonoids, huperzine A and B, ginseng, curcumin, melatonin, and trolox.
What was found
The abstract provides no quantitative data or effect estimates. It reports that hybrid molecules and natural flavonoids exhibit in vitro activity including acetylcholinesterase and butyrylcholinesterase inhibition, reactive oxygen species scavenging, chelation of redox-active copper and iron, suppression of Fenton reactions, destabilization of amyloid fibrils, and modulation of inflammatory and kinase signaling pathways.
Why it matters
The review outlines the rationale for shifting from single-target therapies to multi-functional agents capable of concurrently addressing multiple interconnected pathological features of Alzheimer's disease.
Limits
As a narrative review, it presents no original experimental data, systematic search protocol, or quantitative meta-analysis. The findings rely heavily on in vitro and preclinical models, with major translational challenges regarding human bioavailability, optimal dosage, therapeutic timing, and clinical efficacy remaining unaddressed.
Cited by
- supports Quercetin, resveratrol, and curcumin act as iron and copper chelators.